CHICAGO – May 14, 2014 – First Analysis acted as the exclusive placement agent in a $13.5 million growth capital raise, closed in April 2014, for Apixio Inc. - a leading provider of big data solutions for healthcare analytics. First Analysis provided advisory expertise to Apixio throughout the transaction, including preparation, positioning, investor coordination and contact, due diligence and negotiation.

The equity investment was led by Bain Capital Ventures, who has extensive investment and operating experience in Healthcare Technology. This capital infusion will enable Apixio to scale its sales and operations, further strengthen its proprietary technology and IP, and accelerate the commercialization of additional service offerings.

“First Analysis was instrumental to the successful outcome of this transaction. Their industry expertise and strong venture capital relationships helped push our conversations with investors forward, giving us negotiating leverage and delivering very competitive term sheets from top tier firms,” said Shawn Dastmalchi, CEO of Apixio. “We are very excited about working with Bain Capital Ventures in the next phase of our growth plan.”

About Apixio

Headquartered in San Mateo, CA, Apixio’s big data analytics solution extracts unstructured data from the health system, applies natural language processing and machine learning technology to provide automated actionable insights based on clinical information that enable payors and providers to maximize revenue from risk-based outcome payment models. By using the Company’s HCC Optimizer software to accurately code the disease burden of its members, Medicare Advantage plans can ensure that they receive appropriate reimbursement while minimizing audit risk.

For more information about this transaction, or with questions about how we can assist you or your clients, please contact the following First Analysis representatives: